ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

ENVB Enveric Biosciences Inc

0,9595
0,0297 (3,19%)
Vor Marktöffnung
Zuletzt aktualisiert: 11:38:53
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Enveric Biosciences Inc ENVB NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,0297 3,19% 0,9595 11:38:53
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
0,9298
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
26.3.202412:00BWEnveric Biosciences Reports Financial Results and Provides..
19.3.202412:00BWEnveric Biosciences Signs Non-Binding Term Sheets to Pursue..
12.3.202412:00BWEnveric Biosciences Announces New Patent Issuances..
11.3.202417:35EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
11.3.202413:00EDGAR2Form 8-K - Current report
29.2.202413:00EDGAR2Form 8-K - Current report
29.2.202413:00BWEnveric Biosciences Signs Non-Binding Term Sheets to Pursue..
26.2.202422:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26.2.202422:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26.2.202422:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.2.202414:00BWEnveric Biosciences Agrees to Sell Cancer-Targeting..
21.2.202414:05EDGAR2Form 8-K - Current report
21.2.202414:00BWEnveric Biosciences Unveils Library of Preclinical Compounds..
14.2.202421:36EDGAR2Form SC 13G - Statement of acquisition of beneficial..
09.2.202414:05EDGAR2Form 8-K - Current report
06.2.202416:17EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05.2.202423:09EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
24.1.202414:05EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
23.1.202406:15EDGAR2Form EFFECT - Notice of Effectiveness
11.1.202422:43EDGAR2Form S-3 - Registration statement under Securities Act of..
08.1.202422:42EDGAR2Form 8-K - Current report
03.1.202414:05EDGAR2Form 8-K - Current report
29.12.202322:43EDGAR2Form 8-K - Current report
29.12.202314:52BWEnveric Biosciences Announces Exercise of Warrants and..
28.12.202314:05EDGAR2Form 8-K - Current report
28.12.202314:00BWEnveric Biosciences Selects EB-003 as Lead Drug Candidate..
27.12.202314:05EDGAR2Form 8-K - Current report
27.12.202314:00BWEnveric Biosciences Reports Year End Progress for..
20.12.202314:00BWEnveric Biosciences to Participate in Biotech Showcase 2024..
06.12.202322:00EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
05.12.202314:05EDGAR2Form 8-K - Current report
05.12.202314:00BWEnveric Biosciences Selects Development Candidates from..
01.12.202322:31EDGAR2Form S-1/A - General form for registration of securities..
29.11.202314:18EDGAR2Form 8-K - Current report
29.11.202314:00BWEnveric Biosciences Receives Notice of Allowance from USPTO..
27.11.202314:00BWEnveric Biosciences Announces Manuscript Describing the..
24.11.202314:00BWEnveric Biosciences Announces Presentation of Two Posters at..
22.11.202322:30EDGAR2Form 8-K - Current report
13.11.202322:10EDGAR2Form 8-K - Current report
13.11.202322:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13.11.202322:01BWEnveric Biosciences Reports Third Quarter 2023 Corporate and..
06.11.202314:05EDGAR2Form 8-K - Current report
02.11.202322:29EDGAR2Form 8-K - Current report
31.10.202313:05EDGAR2Form 8-K - Current report
31.10.202313:00BWEnveric Biosciences Receives Notice of Allowance from USPTO..
20.10.202314:05EDGAR2Form 8-K - Current report
20.10.202314:00BWEnveric Biosciences to Present at the Centurion One 5th..
18.10.202314:05EDGAR2Form 8-K - Current report
18.10.202314:00BWEnveric Biosciences Initiates GLP Toxicology & Safety..
11.10.202314:05EDGAR2Form 8-K - Current report

Kürzlich von Ihnen besucht

Delayed Upgrade Clock